

Our ref: IG/FOI/24.R.267

29 July 2024

Sent via email to: [REDACTED]

Dear [REDACTED]

## Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 8 July 2024, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require.

For ease of reference your request is set out below and my response follows.

### Your Freedom of Information (FOI) Request:

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel

- Epcoritamab
- Loncastuximab tesirine
- Glofitamab
- Any other SACT
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatments

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatment

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

Powys Response:

Q1a. Powys Teaching Health Board (PTHB) is a non-acute care provider, and therefore does not directly provide these services. PTHB commissions services from several Welsh health boards and English provider organisations. I therefore recommend that you contact the providers from whom the health board commissions services:

Health Trust/ Organisation	FOI Contact Details
Gloucester Hospitals NHS Foundation Trust	<a href="mailto:ghn-tr.foi@nhs.net">ghn-tr.foi@nhs.net</a>
Shrewsbury & Telford Hospital NHS Trust	<a href="https://www.sath.nhs.uk/about-us/freedom-of-information/make-an-enquiry/">https://www.sath.nhs.uk/about-us/freedom-of-information/make-an-enquiry/</a>
The Royal Wolverhampton NHS Trust	<a href="mailto:rwh-tr.foi@nhs.net">rwh-tr.foi@nhs.net</a>
Wye Valley NHS trust	<a href="https://www.wyevalley.nhs.uk/about-us/information-requests.aspx">https://www.wyevalley.nhs.uk/about-us/information-requests.aspx</a>

Health Board/ Organisation	FOI Contact Details
Aneurin Bevan University Health Board	<a href="mailto:FOI.ABB@wales.nhs.uk">FOI.ABB@wales.nhs.uk</a>
Betsi Cadwaladr University Health Board	<a href="mailto:bcu.foi@wales.nhs.uk">bcu.foi@wales.nhs.uk</a>
Cardiff & Vale University Health Board	<a href="mailto:FOI.Requests@wales.nhs.uk">FOI.Requests@wales.nhs.uk</a>
Cwm Taf Morgannwg University Health Board	<a href="mailto:Freedomofinformation@wales.nhs.uk">Freedomofinformation@wales.nhs.uk</a>

Hywel Dda University Health Board	<a href="mailto:FOI.hyweldda@wales.nhs.uk">FOI.hyweldda@wales.nhs.uk</a>
Swansea Bay University Health Board	<a href="mailto:FOIA.Requests@wales.nhs.uk">FOIA.Requests@wales.nhs.uk</a>
Velindre University Health Board	<a href="mailto:Foi.vunhst@wales.nhs.uk">Foi.vunhst@wales.nhs.uk</a>

Q1b. Powys Teaching Health Board does not commence treatment for this condition. The information requested will be held by the providers.

Q2 – Q4. Powys Teaching Health Board (PTHB) does not initiate or continue treatment with the medicines included in this FOI request. Patients requiring access to these medicines would be referred to and treated by specialist providers outside Powys. We therefore recommend that you approach our providers for this information directly.

Q5. I can confirm that Powys Teaching Health Board does not participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL).

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via [powysfoi.foi@wales.nhs.uk](mailto:powysfoi.foi@wales.nhs.uk)

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



**Kate Wright**  
**Medical Director**

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.